CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 412 enrolled
Drug / intervention
Trazodone Hydrochloride (HCl) Extended-Release Tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00775203
NCT00775203Phase 3Completed
CompareCT.gov

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

Labopharm Inc.·interventional·Posted Oct 20, 2008·Updated Apr 27, 2012

In Brief

A Phase 3 clinical trial evaluating Trazodone Hydrochloride (HCl) Extended-Release Tablets and Placebo for Major Depressive Disorder. Completed, enrolled 412 participants across 36 sites in 2 countries.

Detailed Summary

The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 20, 2008
Enrollment StartJun 1, 2007
Primary CompletionNov 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.7 years ago

Interventions

Trazodone Hydrochloride (HCl) Extended-Release Tabletsdrug

Placebodrug